<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[medical trip China]]></title><description><![CDATA[Global Care Awaits in China]]></description><link>https://www.chinacurelink.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Fri, 07 Aug 2026 04:53:13 GMT</lastBuildDate><atom:link href="https://www.chinacurelink.com/zh/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[到中国看病2026指南：最高省 70% 医疗费 ]]></title><description><![CDATA[重点摘要 中国正迅速成为全球医疗旅游的重要目的地。 2025 年，中国医院共接待约 128 万人次国际患者，较三年前增长 73.6%，主要受益于更低的医疗费用、更快的就诊速度以及高水平专科医疗服务。 与美国自费医疗相比，患者通常可节省 40%–70% 的费用。 中国顶级医院通常可在 24–48 小时内完成 MRI 或 CT 检查，专科预约等待时间更短，并提供透明的双语费用清单。医疗成本较低主要得益于国家集中药品采购和公立医院统一收费制度。 选择合适的医院，比选择城市更重要。 国际患者应优先选择 三级甲等医院（Tertiary Grade-A），重点确认医生经验、国际患者服务、双语医疗文件以及相关疾病治疗数量。 充分准备可有效避免延误与额外费用。 成功的赴华医疗通常包括：出发前病例评估、书面费用报价、办理适当签证（S1/S2 或符合条件的免签）、医疗资料翻译、术后恢复安排，以及与本国医生协调后续随访。 ChinaCureLink 简化跨境就医流程。 作为 Medebound HEALTH 旗下品牌，凭借 10 多年经验 和 服务全球 3000 多位患者...]]></description><link>https://www.chinacurelink.com/zh/post/going-to-china-for-medical-treatment</link><guid isPermaLink="false">6a74bad722f2ed6db245941d</guid><category><![CDATA[Blog]]></category><pubDate>Thu, 06 Aug 2026 17:29:53 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_24dcd51ea73f40a0951b632acbff9f67~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Case Study: Twice-Relapsed Lymphoma, One CAR-T Infusion, and a 60-Day Watch That Ended in Remission]]></title><description><![CDATA[Key Takeaways Complete remission after twice-relapsed disease: A 62-year-old patient with large B-cell lymphoma who had relapsed after both first- and second-line chemotherapy reached a pre-discharge scan showing no detectable tumor and normalized blood work roughly two months after a single CAR-T infusion. This was not a first-try case: standard chemotherapy controlled her disease twice, and failed twice — by the time she was referred for CAR-T, second-line treatment had only bought...]]></description><link>https://www.chinacurelink.com/post/case-study-twice-relapsed-lymphoma-one-car-t-infusion</link><guid isPermaLink="false">6a733bd96f3a9867f4d8619f</guid><category><![CDATA[Cases]]></category><pubDate>Wed, 05 Aug 2026 13:53:13 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Case Study: After Two Relapses and an Eight-Year Wait, a 70-Year-Old Foreign Patient Finally Received BCMA CAR-T Therapy for Multiple Myeloma in China]]></title><description><![CDATA[Key Takeaways A 70-year-old international patient with relapsed multiple myeloma received BCMA-targeted CAR-T cell therapy at a top-ranked 3A-grade hospital in Xi'an, China — and saw his disease burden drop significantly, with the medical team reporting effective disease control after treatment. This wasn't his first attempt. He first sought CAR-T treatment at the same hospital in 2016, but didn't meet that trial's eligibility criteria at the time. He relapsed twice in the years that followed...]]></description><link>https://www.chinacurelink.com/post/case-study-bcma-car-t-for-multiple-myeloma-international-patient</link><guid isPermaLink="false">6a72bb3a6f3a9867f4d7201c</guid><category><![CDATA[Cases]]></category><pubDate>Wed, 05 Aug 2026 05:36:07 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_5e3f9765403043188794e278818f6e65~mv2.png/v1/fit/w_1000,h_768,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Case Study: China's DLBCL CAR-T Patient Achieves Complete Remission — Discharged Just 3 Weeks After Infusion]]></title><description><![CDATA[Key Takeaways Ms. Chen became the first patient in China to achieve complete remission on a commercially approved CAR-T product, days after the drug's national approval — treated at a top-ranked 3A-grade hospital in Shanghai. She had relapsed/refractory diffuse large B-cell lymphoma (DLBCL) — a group in which roughly 40–50% of patients relapse after first-line treatment, and 73% of relapsed/refractory patients fail to reach remission even with second-line therapy and beyond. From prescription...]]></description><link>https://www.chinacurelink.com/post/dlbcl-case-study-china-s-first-ever-commercial-car-t-patient</link><guid isPermaLink="false">6a6989d3eb310bed118a0028</guid><category><![CDATA[Cases]]></category><pubDate>Wed, 29 Jul 2026 05:42:54 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Case Study: Wheelchair-Bound With Bone-Wide Lymphoma, She Was Cancer-Free on PET/CT One Month After CAR-T Therapy at a Shanghai Hospital]]></title><description><![CDATA[Key Takeaways A patient with refractory, bone-metastatic lymphoma showed all lesions gone on PET/CT roughly one month after a single CAR-T cell infusion at a top-ranked 3A-grade cancer hospital in Shanghai — one of China's leading oncology centers. This was a case where standard treatment, salvage chemotherapy, and even newer targeted therapies had already failed — the disease had spread through her entire skeleton, causing pathological fractures and leaving her unable to walk. CAR-T was...]]></description><link>https://www.chinacurelink.com/post/car-t-case-study-bone-wide-lymphoma</link><guid isPermaLink="false">6a6981d62d76e381b883a210</guid><category><![CDATA[Cases]]></category><pubDate>Wed, 29 Jul 2026 05:02:39 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_4dfd2ad218854c01a84bdba92bd0a6cd~mv2.png/v1/fit/w_1000,h_700,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Pediatric CAR-T Case Study: How a Chinese Boy Beat Leukemia With CAR-T Therapy — and Stayed Cancer-Free for 3+ Years Without a Matched Donor]]></title><description><![CDATA[Key Takeaways A child with relapsed acute lymphoblastic leukemia (ALL) achieved complete remission within 4 weeks of a single HLA-haploidentical allogeneic CAR-T infusion, and remained cancer-free at the 3-year follow-up mark — the longest reported cancer-free survival for this specific protocol in China at the time. The "Beijing Protocol" solves CAR-T's biggest access problem: donor scarcity. Unlike standard autologous CAR-T (which requires collecting a patient's own T cells), this approach...]]></description><link>https://www.chinacurelink.com/post/pediatric-car-t-case-study-how-a-chinese-boy-beat-leukemia-with-car-t-therapy</link><guid isPermaLink="false">6a69722d2d76e381b8837ad9</guid><category><![CDATA[Cases]]></category><pubDate>Wed, 29 Jul 2026 04:04:40 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Advanced Cancer Therapies in China: Proton, Immunotherapy &#38; Targeted Therapy Guide (2026)]]></title><description><![CDATA[Key Takeaways "Advanced cancer treatment in China" covers three distinct technologies, not one thing — proton/heavy-ion radiotherapy, immunotherapy, and targeted therapy. China's real edge is regulatory speed on specific drugs and a mature, lower-cost particle-therapy network — not a general claim of "better medicine." The seven drugs driving this access gap have published trial results, not just approval — objective response rates ranging roughly 45–96% depending on the drug and cancer, in...]]></description><link>https://www.chinacurelink.com/post/advanced-cancer-therapies-in-china-proton-immunotherapy-targeted-therapy-guide-2026</link><guid isPermaLink="false">6a59ba9a0ff39938e1cdc369</guid><category><![CDATA[Blog]]></category><pubDate>Fri, 17 Jul 2026 05:41:42 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment in China for Canadian Patients: Real Costs, Regulatory Status &#38; Safety Guide (2026)]]></title><description><![CDATA[Key Takeaways Know what "stem cell treatment" means: Hematopoietic stem cell transplant (HSCT) is a well-established treatment for leukemia, lymphoma, and certain blood disorders, while many direct-to-consumer stem cell injections for chronic conditions remain unproven and have been the subject of Health Canada warnings since 2019. China offers significantly lower HSCT costs than the U.S.: Published estimates place autologous HSCT at around USD $35,000 and allogeneic/haploidentical HSCT at...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-china-canadian-patients</link><guid isPermaLink="false">6a594efccb28250fe83bb6bf</guid><category><![CDATA[Blog]]></category><pubDate>Thu, 16 Jul 2026 22:31:11 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>SecondOpinion Support</dc:creator></item><item><title><![CDATA[Cancer Clinical Trial Matching Services in China: How Patient Matching Works]]></title><description><![CDATA[Key Takeaways A clinical trial matching service reviews your specific diagnosis and treatment history against currently open, registered trials — it exists because no single hospital runs every trial, and no public database filters results down to "trials you actually qualify for." Matching identifies candidates; it does not enroll you. The hospital running the trial makes the final eligibility decision, based on the protocol's own criteria. It is not the same as finding a commercial cancer...]]></description><link>https://www.chinacurelink.com/post/cancer-clinical-trial-matching-services-in-china-how-patient-matching-works</link><guid isPermaLink="false">6a58e9ea01e576df51c75b47</guid><category><![CDATA[Blog]]></category><pubDate>Thu, 16 Jul 2026 15:18:27 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_6b456935b92b4d2e86dca20ee2c3a764~mv2.png/v1/fit/w_1000,h_768,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[How to Join a Cancer Clinical Trial in China: An International Patient's Application Guide]]></title><description><![CDATA[Key Takeaways Enrollment is decided study-by-study, not as a blanket policy — the first task isn't finding "a trial," it's finding which currently open, ChiCTR/NMPA-registered studies actually accept international patients for your specific diagnosis. Eligibility works in layers — general clinical qualification (diagnosis, organ function, treatment history) has to clear before protocol-specific criteria (biomarker status, prior treatment lines, performance status) are even checked....]]></description><link>https://www.chinacurelink.com/post/how-to-join-a-cancer-clinical-trial-in-china-an-international-patient-s-application-guide</link><guid isPermaLink="false">6a584a84f16fbd619a4c22ac</guid><category><![CDATA[Blog]]></category><pubDate>Thu, 16 Jul 2026 03:41:06 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_0684c231dbe0488894402a9877a5bd95~mv2.png/v1/fit/w_1000,h_768,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Clinical Trials &#38; Experimental Cancer Treatment in China: A Patient's Guide (2026)]]></title><description><![CDATA[Key Takeaways China now runs the world's largest oncology clinical trial pipeline — well over a third of all active global oncology trials, with particular depth in CAR-T, bispecific antibodies, and next-generation immunotherapy. A formal clinical trial is not the same as "experimental treatment" more broadly — trial enrollment (through China's NMPA/ChiCTR-registered studies) is a distinct pathway from Hainan's Boao Lecheng zone, which lets a handful of authorized hospitals use...]]></description><link>https://www.chinacurelink.com/post/clinical-trials-experimental-cancer-treatment-in-china-a-patient-s-guide-2026</link><guid isPermaLink="false">6a57ab9aa4777ca49cc321d3</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Wed, 15 Jul 2026 15:57:30 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[How to Get Cancer Treatment in China: A Step-by-Step Patient Guide]]></title><description><![CDATA[Key Takeaways Case review comes first, not treatment selection — a free remote review of your records is what actually determines which treatment pathways (CAR-T, surgery, immunotherapy, clinical trials) apply to your specific cancer. CAR-T total cost of care in China runs $100,000–$150,000 USD, versus $400,000–$500,000+ for the drug alone in the US — but eligibility depends on relapsed/refractory status and confirmed target-antigen expression, not just diagnosis. Most patients move from...]]></description><link>https://www.chinacurelink.com/post/how-to-get-cancer-treatment-in-china-a-step-by-step-patient-guide</link><guid isPermaLink="false">6a57087aaa2c7341eb4cc7bd</guid><category><![CDATA[Blog]]></category><pubDate>Wed, 15 Jul 2026 05:49:52 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Cancer Treatment Cost in China: A Complete Breakdown for International Patients (2026)]]></title><description><![CDATA[Key Takeaways Cancer treatment in China typically costs 40–80% less than the US, UK, or Singapore for the same modality — the gap is driven by lower drug pricing, lower hospital overhead, and China's centralized drug procurement program rather than a difference in the medicine itself. CAR-T cell therapy runs approximately $100,000–$150,000 total in China, versus $500,000–$700,000+ in the US — the single largest line item most patients will see, and the one worth understanding in the most...]]></description><link>https://www.chinacurelink.com/post/cancer-treatment-cost-in-china-a-complete-breakdown-for-international-patients-2026</link><guid isPermaLink="false">6a565718925133b9bb7f8fab</guid><category><![CDATA[Blog]]></category><pubDate>Tue, 14 Jul 2026 15:49:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Cancer Treatment in China: The Complete Guide for International Patients (2026)]]></title><description><![CDATA[Key Takeaways China's cancer treatment ecosystem is world-class — CAR-T therapy, immunotherapy, precision medicine, and proton therapy are all available at ChinaCureLink partner hospitals. Cost savings are substantial: 40–80% less expensive than the US, UK, or Singapore for most treatment modalities, with CAR-T specifically running approximately $100,000–$150,000 in China versus $500,000–$700,000+ in the US. Access to clinical trials is a significant advantage — China leads globally in CAR-T...]]></description><link>https://www.chinacurelink.com/post/cancer-treatment-in-china-the-complete-guide-for-international-patients-2026</link><guid isPermaLink="false">6a55b854ea99be7096e9feb5</guid><category><![CDATA[Blog]]></category><category><![CDATA[CAR-T]]></category><pubDate>Tue, 14 Jul 2026 05:19:48 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment in China for Australian Patients: Costs, Process, and What to Verify Before You Travel]]></title><description><![CDATA[Key Takeaways Stem cell treatment in China may start from approximately USD 8,000 per treatment round, compared with USD 15,000–50,000+ per round in the United States, making China an attractive option for Australian patients seeking more affordable regenerative medicine. Final costs vary depending on the condition, treatment protocol, number of sessions, and hospital. Safety depends on understanding the treatment's regulatory status. China has a limited number of nationally approved stem...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-australia-china-cost</link><guid isPermaLink="false">6a55389baf57c5abb39d73f0</guid><category><![CDATA[Blog]]></category><pubDate>Mon, 13 Jul 2026 19:41:56 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_0b8f29a1b2674774bd9cd84dea237d5c~mv2.png/v1/fit/w_1000,h_910,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment in China for UAE Patients: Costs, Process, and What to Verify Before You Travel]]></title><description><![CDATA[Key Takeaways Stem cell treatment in China may start from approximately USD 8,000 per treatment round, compared with USD 15,000–50,000+ per round in the United States, making China an increasingly attractive option for UAE patients seeking more affordable regenerative medicine while recognizing that final costs depend on the condition, protocol, and number of treatment sessions. Safety depends on regulatory status—not marketing claims. China currently has a limited number of nationally...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-uae-china-cost</link><guid isPermaLink="false">6a552913af57c5abb39d551e</guid><category><![CDATA[Blog]]></category><pubDate>Mon, 13 Jul 2026 18:33:50 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_8ded147e8cb04b679e78c1eba894c775~mv2.png/v1/fit/w_1000,h_887,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment in China for Saudi Arabian Patients: Costs, Process, and What to Verify Before You Travel]]></title><description><![CDATA[Key Takeaways From $8,000 in China vs. $15,000–$50,000+ in the US: The article estimates stem cell treatment in China may start from USD 8,000 for eligible international patients, while comparable U.S. private-market treatments often range from USD 15,000–$50,000+ per round, with wait times often measured in weeks versus months. Only a limited number of regulated pathways are approved: As described in the article, China has one nationally approved stem cell product for a specific...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-saudi-arabia-china-cost</link><guid isPermaLink="false">6a513cd64edfc4e4ec455064</guid><category><![CDATA[Blog]]></category><pubDate>Fri, 10 Jul 2026 19:01:41 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_bac63881c7174b0ea4ba3a4fb90d038e~mv2.png/v1/fit/w_1000,h_916,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment Indonesia: Why China May Offer a More Accessible Treatment Path]]></title><description><![CDATA[Key Takeaways From approximately $8,000 per round in China: The article says stem cell treatment in China may start at around USD 8,000 per treatment round for eligible international patients, compared with approximately USD 15,000–$50,000+ per round advertised by some U.S. private clinics; neither is a fixed all-inclusive price. 2025 conditional approval for a specific condition: China conditionally approved amimestrocel in 2025 for patients aged 14 and above with steroid-refractory acute...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-indonesia</link><guid isPermaLink="false">6a4e9f7a3d233df4f1f27da2</guid><category><![CDATA[Blog]]></category><pubDate>Wed, 08 Jul 2026 19:32:33 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_447e02e87267408293388d7fb7253b86~mv2.png/v1/fit/w_1000,h_887,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment Malaysia: China vs USA Cost, Safety, and Treatment Options]]></title><description><![CDATA[Stem cell treatment is one of the most searched topics in modern medicine—and one of the easiest to misunderstand. Patients in Malaysia may start researching stem cell therapy after dealing with a chronic illness, joint degeneration, diabetes, an autoimmune condition, neurological symptoms, lung disease, tissue injury, or a health problem that has not improved with standard treatment. The interest is understandable. Regenerative medicine aims to repair, replace, or support damaged cells and...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-malaysia-china</link><guid isPermaLink="false">6a4d381f24d6803bed6a93eb</guid><category><![CDATA[Blog]]></category><pubDate>Tue, 07 Jul 2026 18:04:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_54afc07eb4bb4d12a1142c6b55373dd1~mv2.png/v1/fit/w_1000,h_887,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Stem Cell Treatment Singapore: China vs USA Costs, Access, and What to Know in 2026]]></title><description><![CDATA[Stem cell treatment is one of the most searched and misunderstood areas of modern medicine. Patients in Singapore often begin researching stem cell therapy after being diagnosed with a chronic condition, a degenerative disease, an orthopedic injury, diabetes, autoimmune disease, neurological condition, or a complex health problem with limited conventional options. The interest is understandable. Regenerative medicine aims to repair, replace, or support damaged cells and tissues. But the...]]></description><link>https://www.chinacurelink.com/post/stem-cell-treatment-singapore-china</link><guid isPermaLink="false">6a4d24dba79e22eec7927931</guid><category><![CDATA[Blog]]></category><pubDate>Tue, 07 Jul 2026 16:38:57 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_6fa20802b0394eacbf7af87128bf3c79~mv2.png/v1/fit/w_1000,h_887,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item></channel></rss>